Phase 2 Cardiomyopathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You can be enrolled and receive the first dose of the study medication within 24 hours of having a heart catheter procedure
- Your heart scan (either during the catheter procedure or on ultrasound) showed an abnormal pattern of heart wall movement consistent with a condition called Takotsubo syndrome
- Your condition scores above a certain level of severity based on two specific medical scoring systems (confirm with trial site)
- You are able and willing to give written consent to take part
Who may not be able to join:
- You have been diagnosed with a heart attack or acute heart condition caused by a significant blockage in your coronary arteries, or you have had a procedure to open a blocked artery
- You currently have an active infection confirmed by a positive blood test at the time of joining the study
- You have previously had an allergic reaction to a medication called cyclosporine
- You have previously had an allergic reaction to egg, peanut, or soybean proteins
- You have a history of serious kidney problems (either poor kidney function based on blood tests, or you are currently receiving medical care for severe kidney disease)
- You have a history of liver failure or serious liver disease
- You have very high blood pressure that is not under control at the time of screening for the study
- You are currently taking any medication containing St. John's Wort, or certain other specific medicines including Stiripentol, Aliskiren, Bosentan, or Rosuvastatin at certain doses (confirm with trial site)
- You are currently pregnant, or you are a woman who could become pregnant and have not had a negative pregnancy test or are not using effective contraception
- You have had an immune system disorder in the past 6 months, such as an autoimmune disease, or have tested positive for HIV or hepatitis
- You are currently receiving treatment that suppresses the immune system, chemotherapy, or antibody-based therapy
- You are currently taking part in another clinical trial that involves a treatment or intervention (observational studies without any treatment may be acceptable — confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Norbert Frey, MD, University Hospital Heidelberg
Phone: +496221-56-36266
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Myocardial damage
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.